Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01212367 · ClinicalTrials.gov registry record · Phase 1
Intrapleural Gene Transfer for Pleural Mesothelioma
A Phase 1 study, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT01212367 is a Phase 1 study that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 13 participants.
The verdict
NCT01212367, a Phase 1 study, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
This research will study how to activate the immune system by using gene transfer. Gene transfer involves inserting a specially designed gene into cancer cells. A gene is a part of the genetic code that instructs the cells of our bodies to produce specific compounds (proteins) important for the makeup or function of the cell. The study hypothesis is that repeated doses of SCH 721015 given over a three day interval would result in gene transfer.
Interventions
- BIOLOGICAL SCH 721015
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2009-02 |
| Est. Completion | 2015-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01212367
The ClinicalTrials.gov registry entry for NCT01212367 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SCH 721015 is the first listed.
NCT01212367 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01212367 about?
NCT01212367 is a clinical study titled "Intrapleural Gene Transfer for Pleural Mesothelioma". This research will study how to activate the immune system by using gene transfer. Gene transfer involves inserting a specially designed gene into cancer cells. A gene is a part of the genetic code that instructs the cells of our bodies to produce specific compounds (proteins) important for the make...
What is the current status of trial NCT01212367?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2009-02. Estimated completion is 2015-05.
What interventions are being tested in trial NCT01212367?
The interventions under investigation include: SCH 721015 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01212367?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.